Key U.S. metabolic patent.
MELVILLE, N.Y., November 19, 2015 -- Bio-Restorative Therapies, Inc. (OTCQB:BRTX) was issued a U.S. patent covering methods related to the company's metabolic program (ThermoStem).
The patent allows for the protection of methods of production of generating stem cells and stem cell lines from brown adipose tissue (brown fat) under xeno-free (animal-free) conditions utilizing a proprietary differentiating medium.
The technology is applicable for potential therapeutic uses for treating a wide range of degenerative and metabolic disorders, including but not limited to diabetes, hypertension, cardiac deficiency and obesity.
In addition, this patent allows for the development of novel human brown adipose cell lines that may be used for high-throughput small molecule screens in drug development and other compounds that play a role in regulating a variety of processes.
Brown adipose tissue is a specialized adipose tissue found in the human body that plays a key role in the evolutionarily conserved mechanisms underlying thermogenesis (generation of non-shivering body heat) and energy homeostasis in mammals - long known to be present at high levels in hibernating mammals and human newborns.
This metabolic activity of brown adipose tissue is of great interest as a potential target to treat metabolic disorders and obesity using cell or pharmaceutical intervention.
This is the second patent issued within two months, as the company earlier announced a patent for its curved needle device.
The company said its stem cell technology may someday be used to treat metabolic disorders such as diabetes and hypertension. It hopes to advance the program toward clinical trials."